MedTrace Logo

Feasibility Study: Continuous ECG and Blood Pressure Monitoring With the M2VS Sensor System

NCT07694570 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2026-07-10

No results posted yet for this study

Summary

In this study, the investigators want to find out whether a new wearable sensor system, called the M2VS system, can reliably measure heart activity, blood pressure, and other vital signs over 24 hours during normal daily life.

The investigators also want to compare the M2VS system with the standard devices currently used for long-term heart and blood pressure monitoring, such as a Holter ECG and an ambulatory blood pressure monitor (ABPM). This will provide an estimation of the accuracy of the M2VS system's ECG and blood pressure measurements compared to the standard devices.

The aim of the study is to assess how reliable the M2VS system is in terms of data completeness and how comfortable it is to wear compared with the usual monitoring devices.

In the future, the results of this study may help make the monitoring of heart and blood vessel diseases more comfortable and easier for patients.

Conditions

Interventions

DEVICE

24-hour M2VS system multimodal vital sign monitoring

The study features a dual-device monitoring approach integrated into the clinical routine: Participants receiving standard of care will concurrently wear the M2VS system for a 24-hour recording period.The M2VS system is designed for multimodal vital sign monitoring. It comprises a wearable and an associated belt system. The wearable consists of a battery pack and a recorder unit, that are connected via a sliding mechanism

OTHER

Questionnaire regarding the usability and wearability

Questionnaire regarding the usability and wearability of both the M2VS system and the standard of care device.

Sponsors & Collaborators

  • evismo AG

    collaborator UNKNOWN

  • Bern University of Applied Sciences

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Jens Eckstein, Prof. Dr. · University Hospital, Basel, Switzerland

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07694570 on ClinicalTrials.gov